|
Learn how to use IsoPSA to better determine which patients to defer for biopsy and which to monitor more closely. |
|
Webinar: “Applying IsoPSA's Predictive Power to Guide Patient Monitoring”
|
|
When monitoring patients with prior prostate biopsies, relying on PSA testing can leave clinicians and patients without the clarity needed for confident decision-making. Additionally, it can be a challenge to determine which patients can safely defer biopsy and which may need closer follow-up.
|
|
Join us for a webinar on Dec. 11, 1:30 PM EST, in which Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology, will present recently published longitudinal data demonstrating how a single IsoPSA result can help predict a patient's risk for clinically significant prostate cancer (csPCa) over 30 months.1
|
|
|
|
|
|
Dr. Hafron will discuss how IsoPSA can enhance monitoring, support shared decision-making, and better inform biopsy decisions.
|
|
Register now to explore how IsoPSA can enhance csPCa risk stratification and help improve patient management.
|
|
|
Webinar: Applying IsoPSA's Predictive Power to Guide Patient Monitoring
|
|
Speaker: Jason Hafron, MD, CMO, Michigan Institute of Urology
|
|
Date: Dec. 11, Thursday, 1:30 PM EST
|
In this presentation, Dr. Hafron will discuss:
-
Using IsoPSA to enhance clinically significant prostate cancer (csPCa) risk assessment and support shared decision-making.
-
Recently published longitudinal data that demonstrates IsoPSA's ability to predict csPCa over 30 months with a single result.
-
Applying IsoPSA results to guide patient monitoring and biopsy decision-making.
|
|
|
Discover IsoPSA's Clinical Impact
|
Subscribe to learn how IsoPSA can improve risk assessment and receive updates when new CME programs, webinars, and webinars are released.
-
Abdallah, et al., Urology. 2025 Jan 15:S0090-4295(25)00031-7.
|
|
|
This material concerns IsoPSA, a laboratory developed test from Cleveland Diagnostics, Inc., which is regulated under CLIA and qualified to perform high‑complexity clinical testing. As an LDT, IsoPSA has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
|
|
|
|
